The GPR171 Knockout 143B Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the 143B human osteosarcoma cell line, targeting the GPR171 gene. This product provides a heterogeneous pool of cells carrying GPR171 gene disruption, enabling loss-of-function analyses without clonal selection. The polyclonal format preserves biological variability while eliminating the target gene??s function, making it suitable for experiments where population-level responses are critical. Researchers can use these cells to dissect GPR171-mediated signaling in a bone cancer microenvironment.
The 143B cell line is derived from the TE85 human osteosarcoma line and serves as a well-characterized model for studying osteosarcoma tumorigenesis, invasion, and metastasis. These cells exhibit aggressive in vivo growth and metastatic potential, particularly to the lungs, mirroring clinical osteosarcoma behavior. The 143B line has been extensively used to investigate molecular mechanisms underlying bone cancer progression and to evaluate therapeutic strategies. Its genetic and phenotypic traits provide a robust platform for exploring signaling pathways relevant to osteosarcoma biology.
GPR171 is an orphan G??i/o-coupled GPCR activated by the BigLEN peptide, which is derived from the proSAAS precursor. Upon ligand binding, GPR171 interacts with G??i/o proteins and ??-arrestin, leading to inhibition of adenylyl cyclase and reduced cAMP production. This, in turn, diminishes PKA activity and modulates the ERK1/2 mitogen-activated protein kinase pathway. The receptor is also subject to regulation by GPCR kinases (GRKs). The mechanistic consequence of GPR171 gene disruption in this model is the abrogation of BigLEN-dependent Gi/o signaling, resulting in altered cAMP and phospho-ERK1/2 levels, which can affect downstream cellular processes.
In the 143B osteosarcoma context, GPR171-mediated signaling may influence key cancer cell behaviors. By disrupting GPR171, these knockout cells allow researchers to dissect how the neuropeptide signaling axis contributes to osteosarcoma cell proliferation, migration, and intracellular signaling dynamics. The model is particularly relevant for investigating GPR171??s role in tumor progression and for assessing whether targeting this receptor could alter the aggressive phenotype of osteosarcoma cells. It provides a direct tool to study the interplay between GPCR signaling and oncogenic pathways.
These polyclonal knockout cells are suited for a variety of research applications, including GPCR functional studies, osteosarcoma biology, cancer cell signaling, neuropeptide research, and drug target validation. Typical assays include western blotting and RT-qPCR to assess protein and mRNA expression, cAMP accumulation assays to measure Gi/o activity, phospho-ERK analysis to monitor downstream kinase activation, MTT cell proliferation assays, Transwell migration assays, and immunofluorescence staining. The polyclonal nature of the cells ensures a representation of diverse genetic backgrounds, enhancing the robustness of functional studies. For additional details or ordering, please contact Ascent Research.
